Navigation Links
LifeCare Holdings, Inc. Announces Third Quarter Results
Date:11/14/2007

tinguishment of debt for the nine months ended September 30, 2006 was the result of our repurchasing $3 million in face of our senior subordinated notes for an amount approximating $1.5 million. Partially offsetting the gain was the write-off of capitalized financing cost of $0.1 million recorded in connection with the retirement of these senior subordinated notes.

Excluding the impairment charge and the compensation and benefits accrual for 2007, and the impairment charge, gain on early extinguishment of debt, and the insurance recovery for 2006, expenses increased by $13.7 million from the same period in prior year. Rent expenses increased by $2.1 million during the 2007 period in connection with the increases in bed capacity. Net interest expense increased by $1.9 million during the 2007 period from an increase in LIBOR rates and the increased margin spread as the result of the amendment to our senior secured credit facility discussed further in the Liquidity and Capital Resources section contained herein. The remaining $9.7 million increase in expenses was primarily attributable to an increase in salaries, wages and benefits of $6.5 million, and an increase in outside services, contract labor and other operating expenses of $3.2 million. These increases were due to the result of inflationary increases and the increases in bed capacity and patient days.

Credit Agreement EBITDA

For the nine months ended September 30, 2007, Credit Agreement EBITDA, was $26.5 million, a decrease of $18.9 million, or 41.7% from the prior year period. The decrease in Credit Agreement EBITDA, on a dollar and percentage of net patient service revenue basis, was primarily due to the reduction in revenues associated with the CMS regulatory changes and the increase in expenses discussed previously. However, for the quarter ended September 30, 2007, we exercised a cure right as provided in the credit agreement whereby pro forma adjusted EBITDA for the nine months ended Sep
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine news :

1. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
2. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
3. Siemens Announces Early Termination of Hart-Scott-Rodino Waiting Period For Acquisition of Dade Behring Holdings, Inc.; U.S. Antitrust Clearance Achieved
4. Platinum Underwriters Holdings, Ltd. to Report Third Quarter 2007 Results on October 23, 2007
5. Air Methods Completes Acquisition of FSS Airholdings, Inc., Parent Company of CJ Systems Aviation Group, Inc.
6. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
7. China Shenghuo Pharmaceutical Holdings, Inc. Opens Showcase 12Ways(R) Chinese Herbal Beauty Salon in October
8. NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results
9. Duane Reade Holdings, Inc. to Report Third Quarter 2007 Financial Results
10. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
11. Statement by Bonnie J. Campbell, Former Attorney General of Iowa and Spokesperson for Atlantic Richfield Co., Millennium Holdings, LLC, NL Industries, Inc., and The Sherwin-Williams Company on the Jury Verdict Reached Today in the Thomas (Milwaukee) Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2008)... PHOENIX, May 22 /PRNewswire/ -- TriWest Heal...Telly Awards in the 28th Annual Telly Awards,compe...r the visual arts,community., The awards recogniz...ideo as an effective medium to reach military serv...sources and clinical support tools., "At TriWest,...
(Date:5/22/2008)... IRVINE, Calif., May 22 /PRNewswire/ -- Accen...een formally accepted into Sun,s Authorized,Subcon...Delivery Workforce,to provide improved integration...w relationship, Accenx Technologies will see subst...nt roster, develop a closer working,relationship w...
(Date:5/22/2008)... , LOS ANGELES, May 22 /PRNewswire-USNewswire/ -...used on prevention and recovery from Autism,ADHD ... of the organization,through three major steps:, ...ave joined the Board,of Directors., Ms. McCarthy ...other,who recovered her son Evan from autism. Her ...
(Date:5/22/2008)... First Product That Gives Consumers an All-Natura...robiotics & Prebiotic Fiber, JERICHO, N.Y., May 2...ottage cheese with more healthy benefits hits supe...e Health Cottage Cheese with Pro-Active,Nutrients....ed All-Natural,cottage cheese product, Friendship ...
Breaking Medicine News(10 mins):Health News:TriWest Receives National Awards for Innovative Video Communications to Military Community 2Health News:TriWest Receives National Awards for Innovative Video Communications to Military Community 3Health News:Accenx Technologies Joins Sun's Authorized Subcontractor Program 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 3Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 2Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 3
...Doctors at Indore surgically removed an arrowhead,...ago. Till the weapon was removed surgically the tr...nd normally as if nothing has happened. Gajuram, ...l 7 by an arrow by fellow tribesman Kaliya when he...
...Students in Haryana will get a chance to learn yog...ga in the government schools across// the state. ...he was keen to introduce the yoga classes from thi... attended Ramdev's yoga training camp at the indus...
...The years have not lessened the pain of losing the...red Ashok Trivedi and his wife Meenakshi to run fr...hildren are similarly afflicted. The Trivedis we...ed in 1997. They had tried their best to save her,...
...Researchers at Harvard Medical School have been ab...iphering the value that people attach// to differe...he nature of decision making, when a person needs ...le. To quote the words of Camillo Padoa-Schioppa,...
Other Medicine News:Health News:Distressed Couple Assists Parents Of Mentally Challenged Kids 2Health News:Decision-Making Enabled By Neurons: Value Assigned To Available Choices. 2
(Date:5/21/2008)...rom CHARM Study in Remission at One Year ...T PARK, Ill., May 21 /- Res...ott pivotal studies, CHARM and GAIN,demonstrate t...ted with,HUMIRA(R) (adalimumab) achieved long-term...ively, according to data presentations today at Di...
(Date:5/21/2008)...ighlight Watson,s commitment to urology - ..., Fla., May 21 /- Watson Ph...alty pharmaceutical company, announced,today that ... 3 products at,the American Urological Association... safety trial involving silodosin, an investigatio...
(Date:5/21/2008).../ -- Alba Therapeutics Corporation,announced today...presented,in the Clinical Advances in Celiac Disea...ting in San Diego, California. Results of the rand... larazotide acetate for the,prevention of celiac d...subjects in remission(1) were presented by Daniel ...
(Date:5/21/2008)...long-term survivors validate Jennerex ...SCO and YONGIN-SI, South Korea, May 21 /PRNewswire... Ontario), and its South,Korean partner Green Cros...al results from its first-in-class lead product JX...Oncology. The majority of these end- stage,patient...
Breaking Medicine Technology:Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 2Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 3Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 4Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference 5Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 2Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 3Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology 4Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 1Neurobiological Technologies Announces Pricing of Its 2460 Million Common Stock Offering 1579 2Younger Adults Increasingly Treated for Heart Disease related Conditions 694 1Younger Adults Increasingly Treated for Heart Disease related Conditions 694 2Younger Adults Increasingly Treated for Heart Disease related Conditions 694 3Younger Adults Increasingly Treated for Heart Disease related Conditions 694 4P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 1P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 2P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 3P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 4P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 5P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 6P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 7P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 8P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 9P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 10P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 11P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 12P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 13P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 14P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 15P 26G Reports EPS of 240 92 Up 16 25 Behind 8 25 Sales Growth 4952 16Elan Pharmaceuticals Inc Licenses Software and Databases From GeneGo 4948 1
... /PRNewswire-FirstCall/ --,Alfacell Corporation,s ...s a potent payload in antibody conjugates for canc... Handbook of Therapeutic,Antibodies. , In a chapte...ybak, Ph.D. summarizes preclinical research indica...improves in a number of tumor,models, including no...
...PRNewswire/ -- Treatment of,coronary artery diseas...ient setting, according to a study published today...pitalization rates for heart attacks (acute myocar...to 2005, possibly due,to broader use of preventive...ell as declines in risk factors like smoking. , Th...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
...r transfusion needs. A recognized leader in autotr...ay to add the safety of microfiltration for a vari...ve or postoperative applications, autologous or ho...rovides both convenience and versatility in the re...
This high technology cast plaster cutter saw is very easy and comfortable to use.
Designed to reduce noise to a minimum results in less emotional trauma for patients and less hearing trauma for the clinician. The innovative motor plus saw design delivers high power in a smaller, l
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws.
Medicine Products: